| Literature DB >> 28795492 |
M Itchins1,2,3, P L Chia4,5,6, S A Hayes1,2, V M Howell1,2, A J Gill2,7, W A Cooper2,8,9, T John4,5,6, P Mitchell4,5,6, M Millward10,11,12, S J Clarke1,2,3,13, B Solomon14,15, N Pavlakis1,2,3,13.
Abstract
Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.Entities:
Keywords: ALK; non-small cell lung cancer; resistance; survival; tyrosine kinase inhibitors
Mesh：
Substances：
Year: 2017 PMID： 28795492 DOI： 10.1111/ajco.12754
Source DB: PubMed Journal: Asia Pac J Clin Oncol ISSN： 1743-7555 Impact factor: 2.601